Cowen Downgrades Prevail Therapeutics (PRVL) to Market Perform
Tweet
Share
E-mailGet Alerts PRVL Hot Sheet
Price: $23.00 --0%
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Cowen analyst Yaron Werber downgraded Prevail Therapeutics (NASDAQ: PRVL) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Prevail Therapeutics click here. For more ratings news on Prevail Therapeutics click here.
Shares of Prevail Therapeutics closed at $12.50 yesterday.
You May Also Be Interested In
- Jefferies Downgrades Calix (CALX) to Hold
- Morgan Stanley Downgrades Carrefour SA (CA:FP) (CRRFY) to Equalweight
- Nomura/Instinet Downgrades ICICI Prudential Life Insurance Co Ltd. (IPRU:IN) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
